Vertex Pharma, Obsidian Announce Research Collaboration And Licensing Agreement

Vertex Pharmaceuticals Incorporated (VRTX) and Obsidian Therapeutics have entered a research collaboration and licensing agreement, under which Obsidian will use its cytoDRiVE technology to develop novel regulated gene editing therapy candidates for multiple serious diseases. Obsidian grants Vertex the exclusive option to license worldwide rights to candidates developed under the collaboration.

Vertex will pay Obsidian up to $75 million in upfront payments and research milestones, including an equity investment in Obsidian. Obsidian is eligible to receive up to $1.3 billion in potential payments. Also, Vertex will pay tiered royalties on future net sales on any products that may result from the collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Green Field Farms Dairy has recalled its Whole Chocolate Milk product as a laboratory analysis indicated that the product was not effectively pasteurized, the U.S. Food and Drug Administration announced. The recall involves 1,242 units of the Whole Chocolate Milk with an expiration date of September 29, 2021. General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing.
Follow RTT